Stock comparison
Haemonetics
Thermo Fisher Scientific
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
TMO
Thermo Fisher Scientific
Market cap
$166.59B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TMO | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 52C | HAE |
| Benjamin Graham | 85A | 72B | HAE |
| Philip Fisher | 60C | 39D | HAE |
| Peter Lynch | 54C | 28F | HAE |
| Joel Greenblatt | 31F | 48D | TMO |
| Charlie Munger | 54D | 51D | HAE |
| Terry Smith | 55D | 44D | HAE |
Side-by-side metrics
| Metric | HAE | TMO |
|---|---|---|
| Market cap | $2.98B | $166.59B |
| P/E (TTM) | 24.8x | 23.8x |
| EV/EBIT | 14.1x | 25.0x |
| ROIC (TTM) | 8.37% | 7.33% |
| Gross margin | 55.74% | 39.41% |
| Net margin | 7.29% | 15.18% |
| Revenue CAGR 5y | 7.65% | 3.25% |
| EPS CAGR 5y | 24.62% | -2.43% |
| Debt / Equity | 1.5x | 0.8x |
| Dividend yield | 0.0% | 0.4% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -2.43%+110%
- Revenue CAGR 5y7.65%vs 3.25%+58%
- EV/EBIT14.1xvs 25.0x+44%
- Gross margin55.74%vs 39.41%+29%
TMO leads on
- Dividend yield0.4%vs 0.0%+100%
- Market cap$166.59Bvs $2.98B+98%
- Net margin15.18%vs 7.29%+52%
- Debt / Equity0.8xvs 1.5x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.